PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer

Ana M. Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A. Barrera, Octavio Burgues, Ana M. Lluch, Huiqin Chen, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam

    Research output: Contribution to journalArticle

    177 Scopus citations

    Abstract

    The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 mm were used for DNA extraction and slides of 3 mm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy - based approach. Median age was 48 years (range: 30-83 years). Tumor subtype included 72% hormone receptor positive/HER2 negative, 20% HER2-positive, and less than 7.8% triple receptor negative. Tissues were available for PTEN IHC in 46 primary tumors and 52 metastases. PTEN was lost in 14 (30%) primary tumors and 13 (25%) metastases. There were five cases of PTEN loss and eight cases of PTEN gain from primary tumors to metastases (26% discordance). Adequate DNA was obtained from 46 primary tumors and from 50 metastases for PIK3CA analysis. PIK3CA mutations were detected in 19 (40%) of primary tumors and 21 (42%) of metastases. There were five cases of PIK3CA mutation loss and four cases of mutation gain (18% discordance). There was an increase of the level of PIK3CA mutations in four cases and decrease in one case from primary tumors to metastases. There is a high level of discordance in PTEN level, PIK3CA mutations, and receptor status between primary tumors and metastases that may influence patient selection and response to PI3K-targeted therapies.

    Original languageEnglish (US)
    Pages (from-to)1093-1101
    Number of pages9
    JournalMolecular cancer therapeutics
    Volume10
    Issue number6
    DOIs
    StatePublished - Jun 1 2011

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., Mills, G. B., & Meric-Bernstam, F. (2011). PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Molecular cancer therapeutics, 10(6), 1093-1101. https://doi.org/10.1158/1535-7163.MCT-10-1089